ASCO 2021: Presentations about whole genome sequencing
At the congress of the American Society of Clinical Oncology (ASCO) on 4-8 June 2021 researchers Kris Samsom and Luuk Schipper of the Dutch Cancer Institute (NKI) have presented their findings on whole genome sequencing.
In the poster presentation
Whole Genome Sequencing (WGS) is feasible in routine clinical care
Kris Samsom of the Dutch Cancer Institute explains the results of their research in which they conclude that WGS is feasible in routine diagnostics.
In the poster presentation
Whole Genome Sequencing (WGS) improves sarcoma diagnosis and patient care
Luuk Schipper of the Dutch Cancer Institute explains how they came to the conclusion in their research that WGS can help improve the diagnosis and the treatment of patients with sarcomas.
More information
- Paper in The Journal of Molecular Diagnostics: Clinical validation of Whole Genome Sequencing for cancer diagnostics
- Interview with Kim Monkhorst, patholoog NKI/AvL about the interim results of WIDE: Whole Genome Sequencing feasible in clinical practice
- More information about WGS and the extensive DNA test: OncoAct.nl
All news
Also read
In search of the optimal treatment strategy for glioblastoma
Patients with recurrent glioblastoma have an unfavorable outlook and few treatment options. The recently launched GLOW study should change this …
Measuring the effects of radiotherapy on cancer may open up avenues for treatment
Radiotherapy works by damaging the DNA of cancer cells. It’s an effective strategy overall, but many cancers have subsets of …
Patients can benefit from whole genome sequencing for immunotherapy
Immunotherapy is an effective treatment for many people with cancer. The number of abnormalities in the DNA of the tumor in …
The complete DNA test is an additional tool to help us discover the origin of the cancer in patients with CUP, often enabling us to identify this primary tumor. In addition, the test often reveals new options for targeted treatment.